Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry

Steinbach, William J.; Marr, Kieren A.; Anaissie, Elias; Azie, Nkechi; Quan, Shun Ping; Meier-Kriesche, Herwig Ulf; Apewokin, Senu; Horn, David L.

doi:10.1016/j.jinf.2012.08.003

Cited by 305 publications

(245 citation statements)

References 32 publications

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…This observation is consistent with a recent nationwide German study which reported that the 17 incidence of IC without candidemia was the same as candidemia [3] occurring among patients with hematologic malignancies [18], an additional 36 IA cases are 4 estimated to occur in patients with other hematologic malignancies. The incidence of IA 5 amongst patients undergoing SOT was estimated using data from a prospective North 6…”

Section: Opportunistic Invasive Fungal Infections 6supporting

confidence: 90%

Serious fungal infections in Canada

Dufresne

Cole

Denning

et al. 2017

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Section: Opportunistic Invasive Fungal Infections 6supporting

confidence: 90%

Serious fungal infections in Canada

Dufresne

Cole

Denning

et al. 2017

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

“…However, it is important to note that both the period of neutropenia prior to the grafting of these cells and chemotherapy-induced neutropenia involve intense immunosuppression of these patients, making these individuals susceptible to various infections that affect treatment outcomes 5 . Invasive fungal infections, particularly aspergillosis, are common in these patients and have high morbidity and mortality rates in immunocompromised patients 6 .…”

Section: Introductionmentioning

confidence: 99%

Assessment of microbiological air quality in hemato-oncology units and its relationship with the occurrence of invasive fungal infections: an integrative review

Menegueti

Ferreira

Silva

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Worldwide aging of the human population has promoted an increase in the incidence of neoplasia, including hematological cancers, which render patients particularly vulnerable to invasive fungal infections. For this reason, air fi ltration in hematooncology units has been recommended. However, scarce literature has assessed the impact of microbiological air quality on the occurrence of fungal infections in this population. We performed an integrative review of studies in the MEDLINE database that were published between January 1980 and October 2012, using the following combinations of keywords: air × quality × HEPA, air × quality × hematology, and airborne fungal infections. The search yielded only 13 articles, suggesting that high-effi ciency fi ltering of the ambient air in hemato-oncology units can prevent the incidence of invasive fungal infections. However, no randomized clinical trial was found to confi rm this suggestion. Currently, there is no consensus about the maximum allowable count of fungi in the air, which complicates fi ltration monitoring, including fi lter maintenance and replacement, and needs to be addressed in future studies.

show abstract

“…The incidence of mold infections is much lower than candidiasis; however, mold infections are a significant cause of morbidity and mortality among immunocompromised patients. The most common invasive mold infections are attributable to Aspergillus fumigatus (Steinbach et al 2012). Infections caused by difficult-to-treat molds such as Mucor spp.…”

Section: The Clinical Problemmentioning

confidence: 99%

Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches

Roemer

Krysan

2014

Cold Spring Harbor Perspectives in Medicine

441

353

View full text Add to dashboard Cite

Invasive, life-threatening fungal infections are an important cause of morbidity and mortality, particularly for patients with compromised immune function. The number of therapeutic options for the treatment of invasive fungal infections is quite limited when compared with those available to treat bacterial infections. Indeed, only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Here we summarize the unmet clinical needs of current antifungal therapy, discuss challenges inherent to antifungal drug discovery and development, and review recent developments aimed at addressing some of these challenges.

show abstract

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry

Cited by 305 publications

References 32 publications

Serious fungal infections in Canada

Serious fungal infections in Canada

Assessment of microbiological air quality in hemato-oncology units and its relationship with the occurrence of invasive fungal infections: an integrative review

Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches

Contact Info

Product

Resources

About